| Biomarker ID | 604 |
| PMID | 21367627 |
| Year | 2011 |
| Biomarker | Stromal cell-derived factor-1 (SDF-1) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Patients with low levels survived longer than those with high levels |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: HR: 5.164 (95% CI: 2.645–10.083); Multivariate: HR: 2.840 (95% CI: 1.203–6.708) |
| Effect on Pathways | Pathways Include:- Binding of chemokines to chemokine receptors, Nuclear signaling by ErbB4,Intestinal immune network for IgA production,HIF-1 transcriptional activity in hypoxia,Interleukin-7 interactions in immune response |
| Experiment | Prostate Cancer Specific Survival VS No Survival |
| Type of Biomarker | Prognostic |
| Cohort | 148 CaP patients who underwent radical prostatectomy for clinically localized disease and 10 samples of benign prostatic hyperplasia (BPH) were chosen for the study. Lymph Node Metastatis Posititve(n=10) and Lymph Node Metastatis Negative (n=138) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | Univariate: p<0.001; Multivariate: p=0.017 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CXCL12 |